Latest news and press releases about Oaktree Acquisition Corp. II (OACC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe.
Price
| Price | $10.78 |
| Market Cap | $265M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 38.12 |
| Price / Book | 1.05 |
| EV / EBITDA | -220.35 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 3.46% |
| Return on Invested Capital | -0.59% |
| Return on Assets | 3.27% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AACB · CGCT · COPL · FACT · MBAV · MLAC · PMTR
Explore sector: Financial Services · Shell Companies
More sections of OACC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks